文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 工程科技 > 电子/电路 > Chemotherapy in osteosarcoma 2004芬兰
侵权投诉

Chemotherapy in osteosarcoma 2004芬兰

92 Acta Orthop Scand (Suppl 311) 2004; 75

Chemotherapy in osteosarcoma

The Scandinavian Sarcoma Group experience

S. Smeland1, T. Wiebe2, T. Böhling3, O. Brosjö4, K, Jonsson5 and T. A. Alvegård6

1Dept of Oncology, The Norwegian Radium Hospital, Oslo, Norway, 2Dept of Paediatric Oncology, Lund University Hospital, Lund,

Sweden, 3Dept of Pathology, Helsinki University Hospital, Helsinki, Finland, 4Dept of Orthopaedics, Karolinska Hospital, Stockholm, Sweden, 5Dept of Radiology, Lund University Hospital, Lund, Sweden, 6Dept of Cancer Epidemiology, Lund University Hospital, Lund, Sweden

sigbjorn.smeland@klinmed.uio.no

Osteosarcoma is the most common bone tumor in children and adolescents. The most common sites are the distal femur and proximal tibia, and some 15–20% of patients have clinically detect-able metastases at the time of diagnosis. Most studies in osteosarcoma include only patients with “classical osteosarcoma”, a good prognostic group of patients without metastases at presentation, extremity localized tumors and age 40 years. However, nonclassical osteosarcoma represents more than 40% of the entire high-grade osteosar-coma population, emphasizing the need for focus also on this group of patients in clinical research (Huvos 1991, Saeter and Bruland 1998).

The modern multidisciplinary approach to the osteosarcoma patients has significantly improved outcome, especially for the patients with classical disease. Before the introduction of intensive poly-agent chemotherapy, 2-year overall survival around 15–20% was reported (Harvei and Solheim 1981, Friedman and Carter 1972). With today s combina-tion of chemotherapy and surgery long-term sur-vival rates of more than 70% have been reported in several studies (Saeter et al. 1991, Bacci et al. 1993, Fuchs et al. 1998, Smeland et al. 2003).Important treatment principles such as neoad-juvant chemotherapy were already established during the pioneering phase in the 70-ties (Rosen et al. 1979, Jaffe 1976). The rationale for preopera-tive chemotherapy was to achieve immediate effect on metastatic disease, facilitate limbsaving surgery by delineation of the primary tumor and third the possibility to tailor the postoperative chemother-

apy by assessment of the histologic response on the resected tumor specimen. Rosen et al. (1982) with the T-10 protocol, reported improved outcome by selection of the postoperative chemotherapy based on the histologic response to preoperative chemotherapy, a strategy since then utilized in all Scandinavian osteosarcoma studies.

Classical osteosarcoma

SSG II

The breakthrough in osteosarcoma treatment in Scandinavia was the SSG (Scandinavian Sarcoma Group) II study (1982–1989), based on Rosen s T-10 protocol. All patients received 4 cources of high-dose methotrexate preoperatively. Good responders continued with a methotrexate, BCD (bleomycin, cyclophosphamide and dactinomyo-cin), doxorubicin combination whilst poor respond-ers were salvaged with replacement of cisplatin for methotrexate (Saeter et al. 1991) The projected 5-year metastases-free and sarcoma-specific sur-vival rates were 56% and 66%, respectively (Table 1, Figure 1). In contrast to the original report by Rosen et al. the salvage approach with exchange of cisplatin for methotrexate to poor responders did not improve outcome for this group of patients with a persistent difference in metastases-free survival of 25%. The importance of methotrexate administration/elimination was emphasized by the correlation between serum levels of methotrexate and histologic response.

第1页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email